M. Schmidt

2.1k citations

10 papers · 1.3k indexed · 1 hit paper · h-index 7

Impact in

Hematology top 0.5%
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
Genetics top 2%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Genetics 7
- Chronic Lymphocytic Leukemia Research 6
- Hemoglobinopathies and Related Disorders 1
- Myeloproliferative Neoplasms: Diagnosis and Treatment 1
Hematology 7
- Acute Myeloid Leukemia Research 6
- Multiple Myeloma Research and Treatments 3
- Blood groups and transfusion 2
- Chronic Myeloid Leukemia Treatments 1

Co-authors: Robert Knight (6 shared papers)Alan F. List (7 shared papers)Kenton Wride (5 shared papers)Gordon W. Dewald (4 shared papers)Peter L. Greenberg (4 shared papers)John M. Bennett (4 shared papers)Azra Raza (4 shared papers)Jerome B. Zeldis (4 shared papers)
Journals: Blood (4 papers)Journal of Clinical Oncology (2 papers)British Journal of Cancer (1 paper)New England Journal of Medicine (1 paper)BMC Cancer (1 paper)
Partner nations: United States Germany

In The Last Decade

M. Schmidt

9 papers receiving 1.2k citations

Hit Papers

align trajectories log scale

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion 2006 · 893 citations

Peers

Countries citing papers authored by M. Schmidt

Since Specialization

Citations

This map shows the geographic impact of M. Schmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Schmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Schmidt more than expected).

Fields of papers citing papers by M. Schmidt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Schmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Schmidt. The network helps show where M. Schmidt may publish in the future.

Co-authors

The 25 scholars most cited alongside M. Schmidt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M. Schmidt Line = papers co-authored together M. Schmidt links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work
1	Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion New England Journal of Medicine ·Alan F. List, Gordon W. Dewald, John M. Bennett, Aristoteles Giagounidis, Azra Raza, Eric J. Feldman, Bayard L. Powell, Peter L. Greenberg, Deborah A. Thomas, Richard M. Stone, Craig B. Reeder, Kenton Wride, John Patin, M. Schmidt, Jerome B. Zeldis, Robert Knight Hit paper breakdown →	2006	893
2	Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q Blood ·Azra Raza, James A. Reeves, Eric J. Feldman, Gordon W. Dewald, John M. Bennett, H. Joachim Deeg, Luke Dreisbach, Charles A. Schiffer, Richard M. Stone, Peter L. Greenberg, Peter Curtin, Virginia M. Klimek, Jamile M. Shammo, Deborah A. Thomas, Robert Knight, M. Schmidt, Kenton Wride, Jerome B. Zeldis, Alan F. List	2007	308
3	CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study British Journal of Cancer ·H. Köppler, K-H Pflüger, I. Eschenbach, R. Pfab, K. Lennert, W Wellens, M. Schmidt, WD Gassel, Todd M. Kolb, R. Häßler, Kurt R. Schumacher, G. v. Speth, Rolf Holle, K. Havemann	1989	18
4	No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer BMC Cancer ·Ellen L. Goode, Csilla I. Szabo, Ludmila Prokunina‐Olsson, Robert A. Vierkant, Zachary S. Fredericksen, Francis S. Collins, Kristin L. White, M. Schmidt, Brooke L. Fridley, Fergus J. Couch	2009	15
5	Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities. Blood ·Azra Raza, James E. Reeves, Eric J. Feldman, H. Joachim Deeg, Luke Dreisbach, Charles A. Schiffer, Jamile M. Shammo, Virginia M. Klimek, Peter L. Greenberg, John M. Bennett, Gordon W. Dewald, Jerome B. Zeldis, Kenton Wride, M. Schmidt, Robert Knight, Alan F. List	2006	10
6	Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q. Blood ·Alan F. List, Gordon W. Dewald, John M. Bennett, Aristoteles Giagounidis, Azra Raza, Eric J. Feldman, Bayard L. Powell, Peter L. Greenberg, Stephen D. Nimer, Jerome B. Zeldis, Kenton Wride, M. Schmidt, Robert Knight	2006	9
7	Two-Stage Pharmacokinetic & Efficacy Study of Lenalidomide Alone or Combined with Recombinant Erythropoietin (EPO) in Lower Risk MDS EPO-Failures [PK-002]. Blood ·Alan F. List, Jeffrey E. Lancet, Magda Melchert, Hussein Saba, Richard M. Lush, Jian Yu, Nianhang Chen, M. Schmidt, Robert Knight	2007	8
8	Venous thromboembolism in patients with myelodysplastic syndrome treated with lenalidomide: Incidence and risk factors Journal of Clinical Oncology ·Nancy A. Brandenburg, Linda K. Weiss, Robert Bwire, M. Schmidt, Robert Knight, Alan F. List	2008	5
9	Erythroid response to lenalidomide (LEN) + recombinant erythropoietin (EPO) and endogenous serum EPO concentration in MDS cytokine-failures Journal of Clinical Oncology ·Jeffrey E. Lancet, Jeffrey Yu, Hussein Saba, Richard D. Lush, M. Schmidt, Kenton Wride, R. Knight, Alan F. List	2008	2
10	Multizentrische Studie zur Behandlung hochmaligner Non-Hodgkin-Lymphome mit Polychemotherapie (CHOPV) und Bestrahlung Oncology Research and Treatment ·H. Köppler, Karl-Heinz Pflüger, I. Eschenbach, E. Loetzke, R. Pfab, K. Lennert, M. Schmidt, W.D. Gassel, Todd M. Kolb, R. Häßler, Karl Schuhmacher, G. von Speth, K. Havemann	1987	0

About M. Schmidt

M. Schmidt is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Molecular Biology and Neurology, having authored 10 papers that have together received 1.3k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (6 papers), Chronic Lymphocytic Leukemia Research (6 papers), Multiple Myeloma Research and Treatments (3 papers), Lymphoma Diagnosis and Treatment (2 papers), Blood groups and transfusion (2 papers), Hemoglobinopathies and Related Disorders (1 paper), Chronic Myeloid Leukemia Treatments (1 paper) and Myeloproliferative Neoplasms: Diagnosis and Treatment (1 paper). The work is most often cited by research in Hematology (1.1k citations), Genetics (548 citations), Emergency Medicine (79 citations), Pathology and Forensic Medicine (131 citations) and Molecular Biology (460 citations). M. Schmidt has collaborated with scholars based in United States and Germany. Frequent co-authors include Robert Knight, Alan F. List, Kenton Wride, Gordon W. Dewald, Peter L. Greenberg, John M. Bennett, Azra Raza, Jerome B. Zeldis, Eric J. Feldman and Deborah A. Thomas. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Cancer, New England Journal of Medicine and BMC Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact